deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01294293

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

A Phase I Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD; NSC# 712227) or in Combination With Weekly Pactilaxel (NSC #673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Sponsor: Gynecologic Oncology Group

Conditions Malignant Ovarian Mixed Epithelial Tumor Ovarian Brenner Tumor Ovarian Clear Cell Cystadenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Cystadenocarcinoma Ovarian Serous Cystadenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Undifferentiated Ovarian Carcinoma
Interventions Diagnostic Laboratory Biomarker Analysis Paclitaxel Pegylated Liposomal Doxorubicin Hydrochloride Pharmacological Study TLR8 Agonist VTX-2337
Updated 7 times since 2017 Last updated: Dec 23, 2014 Started: Mar 31, 2011 Primary completion: Jul 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Malignant Ovarian Mixed Epithelial Tumor and Ovarian Brenner Tumor and is currently completed. Gynecologic Oncology Group leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotCompleted~Feb 2021 – ~Jul 2024 · 41 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Feb 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gynecologic Oncology Group
  • National Cancer Institute (NCI)
Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations